Emerging drugs for the treatment of myelodysplastic syndrome

Philip J. Nivatpumin, Steven D. Gore

Research output: Contribution to journalReview articlepeer-review

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematopoietic stem cell disorders characterised by ineffective haematopoiesis and an increased risk of developing acute myeloid leukaemia. At present, the only curative option is allogeneic stem cell transplantation. However, the majority of patients are not eligible for this therapy, due to excessive treatment-related morbidity and mortality or lack of a suitable donor. As a result, the need for alternative therapies is great. Our improved understanding of the molecular pathogenesis of MDS has resulted in several new promising therapeutic agents. This review will consider the rational development of new agents based on the molecular biology of MDS.

Original languageEnglish (US)
Pages (from-to)569-590
Number of pages22
JournalExpert Opinion on Emerging Drugs
Volume10
Issue number3
DOIs
StatePublished - Aug 2005

Keywords

  • Acute myeloid leukaemia
  • Cytogenetics
  • Differentiation
  • Epigenetics
  • Farnesyltransferase inhibitors
  • Glutathione
  • Histone deacetylase inhibitors
  • Immunomodulatory agents
  • Methyltransferase inhibitors
  • Myelodysplasia
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Emerging drugs for the treatment of myelodysplastic syndrome'. Together they form a unique fingerprint.

Cite this